| P509 | Tumor spheroid model to dissect the interplay between myeloid cells and cancer cells | Elaheh Ahmadzadeh, PhD; Jan Martinek, PhD; Florentina Marches; Chun I. Yu, PhD; A. Karolina Palucka, MD, PhD | Dendritic cell; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
| P510 | Monoclonal antibodies targeting the MerTK receptor de-repress the innate immune response | Diego Alvarado, Ph.D.; Mike Murphy; Laura Vitale, BS; Thomas O'Neill, BA; Andrew Proffitt; Jay Lillquist; Gwenda Ligon; Craig Polson; Anna Wasiuk; Jeffrey Weidlick, BS; Jenifer Widger, BA; Laura Mills-Chen; Andrea Crocker, BS; Colleen Patterson; Russell Hammond; Li-Zhen He, MD; Joel Goldstein, PhD; Lawrence Thomas, PhD; Henry Marsh, BS PhD; Tibor Keler, PhD; Richard Gedrich | Antibody; Antigen presenting cells; Carcinogenesis; Checkpoint blockade; Chemokine; Cytokine; Dendritic cell; Immune suppression; Inflammation; Monocyte/Macrophage |
| P511 | Co-expression of a chimeric NKG2D receptor with membrane bound IL-15 enhances natural killer cell function and long-term persistence in vitro and in vivo | Luxuan Buren; James Trager, PhD; | CAR T cells; NK/NK T cell; Targeted therapy |
| P512 | AO-176, a next generation CD47 antibody, induces immunogenic cell death | Ben J. Capoccia, PhD; Michael J. Donio; Ronald R. Hiebsch; Alun J. Carter; Robyn J. Puro; Benjamin J. Capoccia; W. Casey Wilson; Daniel S. Pereira; Pamela T. Manning; Robert W. Karr; | Antibody; Checkpoint blockade; Immune toxicity; Monocyte/Macrophage |
| P513 | Targeting adenosinergic immunometabolic suppression with engineered natural killer cells for immunotherapy of CD73+ solid tumors | Andrea Chambers, MS; Kyle B. Lupo; Jiao Wang, PhD; Sandro Matosevic, PhD; | Adoptive immunotherapy; Cytokine; Metabolism; NK/NK T cell; Solid tumors; Targeted therapy; Tumor microenvironment |
| P514 | High efficiency electroporation of primary human NK cells | Jian Chen, PhD; Xiaofeng Xia, PhD; | Adoptive immunotherapy; NK/NK T cell |
| P515 | Novel class of small molecule direct STING agonists as potential cancer immunotherapy | Monika Dobrzanska; Stefan Chmielewski, PhD; Magdalena Zawadzka; Adam Radzimierski; Karolina Gluza; Katarzyna Wojcik-Jaszczynska; Maciej Kujawa; Grzegorz Topolnicki; Grzegorz Cwiertnia; Aleksandra Poczkaj; Izabela Dolata; Jolanta Mazurek; Magdalena Mroczkowska; Agnieszka Gibas; Tushar Mahajan; Marcin Les; Wojciech Schonemann; Sylwia Sudol; Kinga Michalik; Magdalena Sieprawska-Lupa; Katarzyna Banaszak; Charles-Henry Fabritius; Karolina Wiatrowska; Agnieszka Adamus; Krzysztof Brzozka | Antigen presenting cells; Cytokine; Dendritic cell; Inflammation; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P516 | SIRPα blockade increases the activity of multiple myeloid lineage cells, enhances dendritic cell cross-presentation, and aids in remodeling the tumor microenvironment | Brian Francica; Brandy Chavez; Erik Voets, Ph.D.; Andrea van Elsas; Hans van Eenennaam, PhD; Meredith L. Leong | Antibody; Antigen presenting cells; Checkpoint blockade; Myeloid cells; Solid tumors |
| P517 | Pan-allele anti-SIRPα antibodies that block the SIRPα–CD47 innate immune checkpoint | Erik Voets, Ph.D.; Paul Vink, BS; David Lutje Hulsik; Marc Paradé; Sanne Spijkers; Inge Reinieren-Beeren; Joost Rens; Wout Janssen, BS; Brian Francica; Meredith L. Leong; Andrea van Elsas; Hans van Eenennaam, PhD; | Antibody; Antigen presenting cells; Checkpoint blockade; Dendritic cell; Granulocyte; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
| P518 | Non-canonical cross-presenting dendritic cells mediate anti-tumor immunity | Ellen Duong, Sc.B.; Stefani Spranger, PhD; | Antigen presenting cells; Dendritic cell; Myeloid cells; Tumor microenvironment |
| P519 | Agonist redirected checkpoint platform (ARC), engineering bi-functional fusion proteins (SIRP -Fc-CD40L), for cancer immunotherapy | George J. Fromm, Jr., PhD; Suresh de Silva, Ph.D.; Taylor H. Schreiber, MD, PhD; | Antigen presenting cells; Checkpoint blockade; Costimulation; Cytokine; Dendritic cell; Immune suppression; Monocyte/Macrophage; T cell; Tumor antigens |
| P520 | Natural killer (NK) cells orchestrate the antitumor activities of Listeria monocytogenes (Lm)-based immunotherapy | Rachelle Kosoff, PhD; Lauren K. Pettit, MS; Nithya Thambi, MS; Kimberly Ramos, BS; Jeff Jones; Skye Kuseryk; Robert G. Petit, PhD; Michael F. Princiotta, MS, PhD; Kim Jaffe, PhD; SANDY HAYES, PhD | Dendritic cell; Gene expression; NK/NK T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P521 | T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects | Daniel Hirschhorn-Cymerman, PhD; Jacob Ricca; Billel Gasmi, MD; Olivier De Henau, MD; Levi M. Mangarin, BS; Sadna Budhu, PhD; Yanyun Li, PhD MD; Czrina Cortez, BS; Cailian Liu, MD; Roberta Zappasodi, PhD; Sean Houghton; Allison Betof; Katherine S. Panageas, PhD; Mario Lacuoture, MD; Tracvis Hollmann, MD PhD; Jean Albrengues, PhD; Mikala Egeblad, PhD; Taha Merghoub, PhD; Jedd D. Wolchok, MD, PhD; | Checkpoint blockade; Costimulation; Immune toxicity; Inflammation; Solid tumors; T cell |
| P522 | Immune-profiling reveals DNAM-1 downregulation in tumor-infiltrating lymphocytes of renal cell carcinoma patients | Veronika Kremer, MSc; Christina Seitz, MSc; Ann-Helen Scherman Plogell, MD; Eugenia Colon, MD, PhD; Evren Alici, MD, PhD; Andreas Lundqvist, PhD | Immune contexture; Immune suppression; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P523 | Engineering responsive multi-functional natural killer cells derived from induced pluripotent stem cells capable of overcoming immunometabolic suppression for immunotherapy of solid tumors | Kyle B. Lupo; Andrea M. Chambers; Jiao Wang, PhD; Sandro Matosevic, PhD; | Immune suppression; NK/NK T cell; Stem cell/cancer-initiating cell; Targeted therapy; Tumor microenvironment |
| P524 | Preclinical characterization of BMS-986299, a first-in-class NLRP3 innate agonist with potent antitumor activity, alone and in combination with checkpoint blockade | Michael Wichroski, Ph.D; Huilin Qi; Jie Fang; Adam Bata; Ramola Sane; Anwar Murtaza, PhD; Ashvinikumar Gavai, PhD; Ragini Vuppugalla; Frederic Reu; Dana Banas; Julie Carman, PhD; Damien Bertheloot; Dennis Dean; Luigi Franchi; Shomir Ghosh; Gary Glick; Jonathan D. Graves; Ana Kitanovic, PhD; Eicke Latz; Xiaokang Lu, BS; Edward Olhava; William Roush; Brian Sanchez; Andrea Stutz; David Winkler, PhD; John Hunt, PhD; Miguel A. Sanjuan, PhD; James Burke | Checkpoint blockade; Cytokine; Dendritic cell; Inflammation; Monocyte/Macrophage; Myeloid cells; Solid tumors |
| P525 | Preclinical characterization of BMS-986301, a differentiated STING agonist with robust antitumor activity as monotherapy or in combination with anti‒PD-1 | Gary Schieven, Ph.D.; Jennifer Brown; Jesse Swanson, BS; Caitlyn Stromko; Ching-Ping Ho, BS; Rosemary Zhang; Bifang Li-Wang; Hongchen Qiu; Huadong Sun; Brian Fink, PhD; Anwar Murtaza, PhD; John Hunt, PhD | Antibody; Checkpoint blockade; Inflammation; NK/NK T cell; T cell; Tumor microenvironment |
| P526 | The potential role of fibroblast activation protein as a natural killer cell immune checkpoint in pancreatic cancer | Louis M. Weiner, MD; Shangzi Wang, PhD; Allison O'Connell, MD/PhD Candidate; | Checkpoint blockade; Coinhibition; NK/NK T cell; Solid tumors; Tumor microenvironment; Tumor stroma |
| P527 | Imprime PGG, a novel cancer immunotherapeutic, engages the complement system to prime innate immune effector functions | Xiaohong Qiu, BS; Ben Harrison, MS; Adria B. Jonas, MS; Anissa S. Chan, PhD; Nadine Ottoson, BS; Keith Gorden, BS; | Checkpoint blockade; Chemokine; Cytokine; Granulocyte; Immune monitoring |
| P528 | Tumor-derived alpha fetoprotein suppression of mitochondrial metabolism via PGC1-α and SREBP-1 expression and activity in human dendritic cells | Patricia M. Santos, PhD; Ashley Menk, BS; Jian Shi, MD; Allan Tsung, MD; Greg M. Delgoffe, PhD; Lisa H. Butterfield, PhD | Antigen presenting cells; Dendritic cell; Immune suppression; Myeloid cells; Metabolism; Tumor antigens |
| P529 | Efficacy and safety profile of AU7R-104, a small molecule targeting CD47/SIRPα pathway | Pottayil Sasikumar, PhD; Chennakrishnareddy Gundala; Wesley Balasubramanian, PhD; Sudarshan Naremaddepalli, PhD; Archana Bhumireddy, MSc; Sandeep Patil, PhD; Amit Dhudashiya; Vijaysai Rayavarapu, MSc; Dodheri Samiulla, PhD; Sanjeev Giri, PhD; Rajesh Eswarappa, Ph.D., DABT., ERT; Kiran Aithal, PhD; Girish Daginakatte, PhD; Murali Ramachandra, PhD | Checkpoint blockade; Monocyte/Macrophage |
| P530 | Novel bispecific antibody targeting NKp30 receptor enhances NK-mediated killing activity against multiple myeloma cells and overcomes CD16A deficiency | Jennifer Watkins-Yoon; Jamie L. Schafer, PhD; Sara Haserlat; Sri Vadde; Xin Kai; Allison Nelson; Lucy Liu; Nora Zizlsperger, PhD; Amanda Oliphant; Michael Schmidt; Robert Tighe, BS; MONIA DRAGHI, PhD | Antibody; Leukemia/Lymphoma; NK/NK T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor evasion; Tumor microenvironment |
| P531 | Redirecting immunometabolic suppression by targeting purinergic signaling enhances immunotherapy of solid tumors with CAR-NK cells | Sandro Matosevic, PhD; Jiao Wang, PhD; Kyle B. Lupo; Andrea M. Chambers; | Antibody; Cytokine; Immune monitoring; Immune suppression; Metabolism; NK/NK T cell; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P532 | Preclinical characterization of a first-in-class ILT4 antagonist, MK-4830 | Luis A. Zuniga, Ph.D.; Barbara Joyce-Shaikh, B.S.; Douglas C. Wilson; Holly Cherwinski; Yi Chen; Grein Jeff; Eric Muise, MS; Wendy Blumenschein, BA; Xiaoyan Du; Edward Hsieh; Sripriya Dhandapani; Gulesi Ayanoglu; Maribel Beaumont; Shuli Zhang; Michael Rosenzweig, DVM, PhD; Robert Kastelein, PhD; Robert N. Stein, MD PhD; Dennis Underwood, PhD; Milan Blanusa; Rachel Altura, MD; Daniel J. Cua | Antibody; Antigen presenting cells; Checkpoint blockade; Clinical trial; Granulocyte; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; MDSC |
| O37 | A new immunomodulatory strategy of inhibiting the glyco-immune checkpoint axis with EAGLE technology to treat cancer | Li Peng, PhD; Lizhi Cao; Adam Petrone; Lihui Xu, BS; Wayne Galtlin, MS; Michele Mayo; Michal Stanczak; Carolyn Bertozzi; Karl Normington, PhD, MBA; Jeff Brown; Heinz Laubli; Jim W. Broderick, MD; Li Peng, PhD | Antibody; Immune suppression; Targeted therapy; Tumor microenvironment |
| O38 | Remodeling the tumor microenvironment – Targeting Scavenger receptors | Dhifaf Sarhan, PhD; Caroline Driescher, MS.; Silke Sohn, MS.; Salvatore Nania; Rainer Heuchel; Matthias Löhr; Mikael Karlsson | Checkpoint blockade; Immune suppression; Monocyte/Macrophage; MDSC; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment |
